NO20024972L - Blandinger og fremgangsmater for terapi og diagnose av brystkreft - Google Patents

Blandinger og fremgangsmater for terapi og diagnose av brystkreft

Info

Publication number
NO20024972L
NO20024972L NO20024972A NO20024972A NO20024972L NO 20024972 L NO20024972 L NO 20024972L NO 20024972 A NO20024972 A NO 20024972A NO 20024972 A NO20024972 A NO 20024972A NO 20024972 L NO20024972 L NO 20024972L
Authority
NO
Norway
Prior art keywords
diagnosis
therapy
mixtures
methods
breast cancer
Prior art date
Application number
NO20024972A
Other languages
English (en)
Other versions
NO20024972D0 (no
Inventor
Yuqiu Jiang
Davin C Dillon
Jennifer Lynn Mitcham
Jiangchun Xu
Susan L Harlocker
William T Hepler
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/551,621 external-priority patent/US6844325B2/en
Priority claimed from US09/604,287 external-priority patent/US6586572B2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO20024972D0 publication Critical patent/NO20024972D0/no
Publication of NO20024972L publication Critical patent/NO20024972L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20024972A 2000-04-17 2002-10-16 Blandinger og fremgangsmater for terapi og diagnose av brystkreft NO20024972L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/551,621 US6844325B2 (en) 1998-12-28 2000-04-17 Compositions for the treatment and diagnosis of breast cancer and methods for their use
US09/590,751 US6756477B1 (en) 1998-12-28 2000-06-08 Compositions and methods for the therapy and diagnosis of breast cancer
US09/604,287 US6586572B2 (en) 1998-12-28 2000-06-22 Compositions and methods for the therapy and diagnosis of breast cancer
US09/620,405 US6528054B1 (en) 1998-12-28 2000-07-20 Compositions and methods for the therapy and diagnosis of breast cancer
PCT/US2001/012164 WO2001079286A2 (en) 2000-04-17 2001-04-12 Compositions and methods for the therapy and diagnosis of breast cancer

Publications (2)

Publication Number Publication Date
NO20024972D0 NO20024972D0 (no) 2002-10-16
NO20024972L true NO20024972L (no) 2002-12-11

Family

ID=27504757

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024972A NO20024972L (no) 2000-04-17 2002-10-16 Blandinger og fremgangsmater for terapi og diagnose av brystkreft

Country Status (14)

Country Link
US (1) US6528054B1 (no)
EP (1) EP1299417A2 (no)
JP (1) JP5053497B2 (no)
CN (1) CN1646563A (no)
AU (1) AU2001255369A1 (no)
BR (1) BR0110091A (no)
CA (1) CA2406213A1 (no)
HU (1) HUP0301740A2 (no)
MX (1) MXPA02010244A (no)
NO (1) NO20024972L (no)
NZ (1) NZ521865A (no)
PL (1) PL365244A1 (no)
RU (1) RU2344831C2 (no)
WO (1) WO2001079286A2 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7414112B2 (en) * 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
CA2392510A1 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US7354992B2 (en) * 1999-11-30 2008-04-08 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
CA2520675A1 (en) * 2003-03-24 2004-10-07 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Identification, quantification, and characterization of t cells and t cell antigens
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
BRPI0512397A (pt) 2004-06-25 2008-03-04 Takeda Pharmaceutical composto,produto farmacêutico, métodos para suprimir a metástase de cáncer ou o crescimento do cáncer, para prevenir ou tratar uma doença ou condição, para controlar a função placentária, para melhorar a função gonadal, para induzir ou estimular a ovulação, para promover a secreção do hormÈnio gonadotrópico ou promover a secreção do hormÈnio sexual, para suprimir a secreção do hormÈnio gonadotrópico ou suprimir a secreção do hormÈnio sexual, para infra regular hormÈnio gonadrotópico ou hormÈnio sexual, e a proteìna ot7t175 humana, e para realçar a estabilidade no sangue, uso do composto, e, agente para suprimir a secreção do hormÈnio gonadotrópico ou um agente para suprimir a secreção do hormÈnio sexual
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
US20100160275A1 (en) * 2006-09-26 2010-06-24 Lee Eva Y H P Methods and compositions for cancer prevention and treatment
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
CN101974088B (zh) * 2010-11-03 2014-04-02 中国人民解放军军事医学科学院基础医学研究所 乳腺珠蛋白单克隆抗体及其在乳腺癌诊断中的应用
WO2013016126A1 (en) 2011-07-22 2013-01-31 The General Hospital Corporation Therapeutic nanoparticles and methods of use thereof
JP2016214239A (ja) * 2015-05-15 2016-12-22 国立大学法人高知大学 膵がんマーカー
RS60823B1 (sr) 2015-12-04 2020-10-30 Boehringer Ingelheim Int Biparatopski polipeptidi koji antagonizuju wnt signalizaciju u tumorskim ćelijama
WO2017120274A1 (en) * 2016-01-08 2017-07-13 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from protocadherin fat1 as cancer biomarkers
KR102112690B1 (ko) 2017-10-12 2020-05-19 주식회사 이앤에스헬스케어 티오레독신 1 에피토프 및 이에 특이적으로 결합하는 단일클론항체
TWI709188B (zh) 2018-09-27 2020-11-01 財團法人工業技術研究院 基於機率融合的分類器、分類方法及分類系統
RU2736163C1 (ru) * 2019-05-29 2020-11-12 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ интраоперационной диагностики рака молочной железы
CN112724233B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-13、制法和其药物组合物与用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04505547A (ja) 1988-01-04 1992-10-01 イー・アイ・デユポン・ド・ネモアース・アンド・コンパニー 細胞混合物から特定の細胞を単離するための多段アフィニティー法
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
DE69126620T2 (de) 1990-10-18 1997-10-02 Cellpro Inc Vorrichtung und verfahren zur trennung von partikeln mittels eines biegsamen gefässes
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
EP0871768B1 (en) 1995-03-17 2004-07-07 John Wayne Cancer Institute Detection of melanoma metastases with a multiple marker assay
US5668267A (en) 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5922836A (en) 1995-05-31 1999-07-13 Washington University Mammaglobin antigens
US5985564A (en) * 1995-08-16 1999-11-16 President And Fellows Of Harvard College Assay for identifying agents that inhibit chromosome non-disjunction
US5986170A (en) 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
US5891857A (en) 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
EP0941328A1 (en) 1996-11-12 1999-09-15 Incyte Pharmaceuticals, Inc. Human breast tumor-specific proteins
AU6257298A (en) 1997-02-03 1998-08-25 Human Genome Sciences, Inc. Breast cancer specific gene 1
CA2291260A1 (en) 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 human secreted proteins
EP1005544A4 (en) 1997-08-19 2004-07-14 Human Genome Sciences Inc 70 HUMAN, SECRETED PROTEINS
CA2316397A1 (en) * 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
AU3094999A (en) * 1998-03-18 1999-10-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
TW200532020A (en) * 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
JP3422776B2 (ja) 1998-08-04 2003-06-30 ダイアデクスアス・インコーポレーテッド 乳癌を診断、監視、病期決定、造影及び治療する新規な方法
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
DE60044119D1 (de) 1999-01-21 2010-05-20 Abbott Lab Reagentien und verfahren zur erkennung von erkrankungen der brust
AU5047800A (en) 1999-05-28 2000-12-18 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
WO2001037779A2 (en) 1999-11-23 2001-05-31 Diadexus, Inc. A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1261704B1 (en) 1999-11-30 2009-07-01 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof

Also Published As

Publication number Publication date
NZ521865A (en) 2004-07-30
HUP0301740A2 (hu) 2004-06-28
JP5053497B2 (ja) 2012-10-17
RU2002130715A (ru) 2004-03-27
CN1646563A (zh) 2005-07-27
WO2001079286A2 (en) 2001-10-25
EP1299417A2 (en) 2003-04-09
JP2004520802A (ja) 2004-07-15
WO2001079286A3 (en) 2003-01-30
BR0110091A (pt) 2004-02-25
CA2406213A1 (en) 2001-10-25
MXPA02010244A (es) 2003-05-23
AU2001255369A1 (en) 2001-10-30
US6528054B1 (en) 2003-03-04
NO20024972D0 (no) 2002-10-16
RU2344831C2 (ru) 2009-01-27
PL365244A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
NO20024972L (no) Blandinger og fremgangsmater for terapi og diagnose av brystkreft
NO20023402D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft
NO20030714D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av HER-2/NEU-assosierte maligniteter
NO20014769D0 (no) Preparat for behandling og diagnose av bryst cancer og fremgangsmåter for anvendelse derav
NO20010196D0 (no) Sammensetninger og fremgangsmåter for terapi og diagnose av prostatakreft
NO20003853L (no) Forbindelser for terapi og diagnose av lungekreft og metoder for deres anvendelse
NO20016427L (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
NO983183L (no) Blandinger og fremgangsmåte for behandling og diagnose av brystkreft
NO20013002L (no) Blandinger og fremgangsmåter for behandling og diagnose av ovariekreft
NO994932D0 (no) Blandinger og fremgangsmaater for behandling og diagnose av brystkreft
NO20014223D0 (no) Fremgangsmåte for diagnostisering og overvåkning av maligne brystkarsinoma
HK1045332A1 (zh) 用於治療和診斷肺癌的化合物及其使用方法
NO20014804L (no) Forbindelser for immunterapi og diagnose av brystkreft og fremgangsmåter for deres anvendelse
NO20025594L (no) Blandinger og fremgangsmåter for terapi og diagnose av brystkreft
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002348297A8 (en) Proteonomic methods for diagnosis and monitoring of breast cancer
AU5947701A (en) Methods for identification, diagnosis, and treatment of breast cancer
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
EP1532162A4 (en) CC49, ANTI-TAG-72 HUMANIZED FOR DIAGNOSIS AND TREATMENT OF TUMORS IN MAN
NO20014805D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av brystkreft
FI20021617A0 (fi) Diagnostisia ja terapeuttisia menetelmiä
NO20031656D0 (no) Kombinasjon omfattende camptothecin og et stillbenderivat for behandling avcancer
DK1157041T3 (da) Antistoffer til diagnose og behandling af cancer
GB0007754D0 (en) Proteins and their use for diagnosis and treatment of breast cancer
GB0007265D0 (en) Proteins and their uses for diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application